PLA2G12A Mutant Polypeptides for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic disorders such as Type 2 diabetes, elevated glucose levels, dyslipidemia, obesity, and diabetic nephropathy are inadequate, as existing therapies often fail to effectively manage fasting blood glucose levels and insulin resistance.
Innovation Solution
Administration of a therapeutically effective amount of a PLA2G12A polypeptide or its mutant, specifically with mutations at positions H110 or H88, which are administered in a pharmaceutical composition with a pharmaceutically acceptable carrier, to regulate metabolic functions and improve glucose and insulin tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat metabolic disorders, then treatment is provided, but they fail to effectively manage fasting blood glucose levels and insulin resistance
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the PLA2G12A polypeptide sequence. Mutations at positions H110 or H88 alter the protein's functional properties, enabling it to effectively lower blood glucose and insulin levels while improving glucose tolerance. This direct modification of molecular parameters resolves the contradiction by creating a therapeutic agent with enhanced and adaptable metabolic regulatory capabilities.
2Reliability
If PLA2G12A polypeptide is administered to treat metabolic disorders, then blood glucose and insulin levels are lowered, but the wild-type form has limited efficacy compared to mutant forms
Solution Approach 1:
The patent applies local quality by introducing specific mutations at particular amino acid positions (H110 or H88) within the PLA2G12A polypeptide. Rather than modifying the entire protein structure, localized changes at these specific residues enhance the protein's metabolic regulatory function. This approach resolves the contradiction by achieving superior therapeutic efficacy through targeted, minimal structural modifications rather than comprehensive redesign.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PLA2G12A polypeptide or its mutant effectively lowers blood glucose and insulin levels, improves glucose tolerance, and reduces body weight, thereby addressing the metabolic disorders mentioned, with the mutant form (PLA2G12A-H110L) showing superior efficacy compared to the wild-type PLA2G12A.
Implementation Method 1
Phospholipase A2 enzymes, including PLA2G12A, catalyze the calcium-dependent hydrolysis of phospholipids at the sn-2 position to yield fatty acids and lysophospholipids
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.